

Special Issue

Small Molecule Antivirals

Message from the Guest Editors

Viruses are obligate intracellular parasites that lack the assets for self-reproduction, so they take over host cell's metabolic pathways to complete a viral life cycle. Together, they encode specific viral proteins that are vital for producing progeny virions. The inhibition of both viral or host proteins involved in the viral replication is challenging; the obtained compounds may be toxic or lack selectivity. For this reason, the antiviral research of potent and selective antiviral drugs is still critical, as the recent coronavirus pandemic pointed out. This Special Issue aims to collect original research articles, reviews, or letters focused on the identification of synthetic, semi-synthetic, or naturally derived molecules related with antiviral activity, as well as the study of mechanisms of action and mechanisms of drug resistance. Furthermore, identification of new antiviral targets, or potential ones, are more than welcome.

Guest Editors

Dr. Antonio Carta

Surgical and Experimental Medical Sciences, Università degli Studi di Sassari, Sassari, Italy

Dr. Roberta Ibba

Department of Medicine, Surgery and Pharmacy, University of Sassari, Via Muroni 23A, 07100 Sassari, Italy

Deadline for manuscript submissions

closed (31 May 2023)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/114832

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).